Analyst consensus rating
Sinovac Biotech Analyst Rating: Buy
Direct answer
Sinovac Biotech's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.52.
Forecast evidence checked October 28, 2026.
Get free Sinovac Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.47
- Average price target
- $3.52
- High price target
- $6.00
- Low price target
- $1.50
- Low target gap
- -76.8%
- Target upside
- -45.6%
- High target gap
- -7.3%
- Target range width
- 69.6%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- October 28, 2026
- Valid through
- November 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sinovac Biotech?
Sinovac Biotech has a verified Buy consensus. The same dataset has an average price target of $3.52.
How far are Sinovac Biotech's low and high targets from the recorded price?
The low target implies -76.8%, while the high target implies -7.3%.
How many analysts are included in Sinovac Biotech's consensus?
The verified consensus includes 6 analysts.
How is Sinovac Biotech's target upside or downside calculated?
The average target of $3.52 is divided by the recorded price of $6.47, then one is subtracted to produce -45.6%. This does not guarantee a future return.
When was Sinovac Biotech's analyst forecast verified?
The data was verified on 2026-10-28. The dataset is valid through 2026-11-04.